Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (IMNM) is a cutting-edge biotechnology firm specializing in the development of innovative cancer immunotherapies. Grounded in leveraging the human immune system, Immunome's unique approach involves utilizing the 'most highly educated' immune systems from patients who have successfully fought off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and patient-derived, native antibodies that target those antigens.
The company employs a comprehensive suite of high-content screening technologies to identify specific and high-affinity antibodies that hold significant therapeutic potential. By harnessing these advanced techniques, Immunome aims to revolutionize cancer treatment and improve patient outcomes.
Immunome's primary pipeline includes promising preclinical and clinical assets, such as IM-1021 targeting fibroblast activation protein (FAP) and IM-4320, aimed at transforming the therapeutic landscape of oncology and infectious diseases, including COVID-19. The company is strategically positioned within the U.S. and focuses on establishing a broad spectrum of assets that can be efficiently developed through successive value inflection points.
The latest developments and achievements of Immunome reflect its commitment to innovation and excellence in the biopharmaceutical sector. The latest news showcases significant milestones, partnerships, and advancements in their research and development efforts, further solidifying their reputation as leaders in the field of antibody therapeutics.
Immunome (Nasdaq: IMNM) has appointed Dr. Franklyn G. Prendergast to its Board of Directors, enhancing its leadership during a pivotal transition from preclinical to clinical stages. Dr. Prendergast, recognized for his extensive medical and academic experience, aims to contribute to the development of antibody therapeutics targeting diseases with unmet needs. Concurrently, Michael Widlitz, a long-serving director, will transition to an advisory role in Medical Affairs. This strategic management change is expected to leverage Immunome's innovative platform for therapeutic advancement.
Immunome, Inc. (Nasdaq: IMNM) has announced that Purnanand Sarma, Ph.D., President and CEO, will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 8:00 a.m. ET. Interested parties can access the live audio webcast through the Investor Relations section of the company's website, with a replay available for 30 days after the event. Immunome focuses on developing first-in-class antibody therapeutics using its human memory B cell discovery engine, targeting oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM) announced a $4.3 million funding increase from the U.S. Department of Defense, raising total support to $17.6 million for its antibody cocktail, IMM-BCP-01, aimed at combating SARS-CoV-2. This additional capital will facilitate the expansion of clinical studies following FDA feedback. The antibody cocktail, comprising three monoclonal antibodies, targets multiple SARS-CoV-2 variants with high affinity. Immunome is working towards an IND filing for IMM-BCP-01 in late 2Q/early 3Q 2021.
Immunome, a biopharmaceutical company focused on antibody therapeutics, reported its Q1 2021 financial results, revealing a net loss of $3.9 million and R&D expenses of $2.0 million. The company announced significant advancements, including the discovery of antibodies neutralizing SARS-CoV-2 variants and plans for an IND filing for the IMM-BCP-001 cocktail in late Q2 or early Q3 2021. Additionally, Immunome appointed Dr. Dennis Giesing as Chief Development Officer and Corleen Roche as Chief Financial Officer. A $27 million private placement is expected to fund operations through 2022.
Immunome, Inc. (Nasdaq: IMNM) announced antibody selection for its IMM-BCP-01 cocktail, showing effectiveness against SARS-CoV-2 variants in preclinical tests. The cocktail, comprising three monoclonal antibodies, demonstrated full neutralization against several variants, including those resistant to current therapeutics. The company plans to file an IND for IMM-BCP-01 in late Q2/early Q3 2021, supported by a $13.3 million agreement with the U.S. Department of Defense. Immunome aims to pioneer treatments for oncology and infectious diseases through its patient memory B cell platform.
Immunome (Nasdaq: IMNM) has entered into a definitive securities purchase agreement to sell its equity securities in a private placement, securing approximately $27 million in gross proceeds. The deal involves the sale of 1,000,000 units at $27.00 per unit, each comprising one share of common stock and a warrant for an additional half share at $45.00 per share. Funds will support the development of its oncology and infectious disease portfolio, including COVID-19. The transaction is expected to close on April 28, 2021, pending customary conditions.
Immunome, Inc. (Nasdaq: IMNM) has appointed Corleen Roche as the new Chief Financial Officer. Roche, with extensive experience in corporate finance in the biopharmaceutical sector, previously served as U.S. CFO for Biogen. Her appointment is expected to enhance Immunome's growth into a clinical-stage company, strengthening its financial strategy and business development efforts. Roche aims to leverage her expertise to advance Immunome's therapeutic pipeline, which focuses on oncology and infectious diseases, including COVID-19.
Immunome (Nasdaq: IMNM) announced the appointment of Dennis Giesing, Ph.D., as Chief Development Officer, effective immediately. Dr. Giesing brings over 35 years of pharmaceutical experience, having previously worked at Johnson & Johnson Oncology and Taris Biomedical. His role will include leading product development and clinical strategies, with two IND filings planned for 2021. CEO Purnanand Sarma expressed confidence in Dr. Giesing's ability to advance Immunome's antibody therapeutics aimed at oncology and infectious diseases, including COVID-19.
Immunome, Inc. (NASDAQ: IMNM) reported its financial results for Q4 and the full year ending December 31, 2020. The company raised $44.9 million through its IPO, enhancing its financial position with cash and equivalents of $39.8 million as of year-end. For Q4, R&D expenses were $1.8 million, while total annual R&D expenses reached $7.5 million. General and administrative expenses for Q4 were $2.2 million, totaling $4.8 million for the year. The net loss for Q4 was $4.1 million ($0.40 per share), and $17.8 million ($5.26 per share) for the full year.
Immunome, Inc. (Nasdaq: IMNM) announced the advancement of its first oncology program targeting IL-38 into IND-enabling studies, with an IND filing expected in H2 2021. The IL-38 target was identified from a B cell sample of a head and neck cancer patient. IL-38 acts as a novel innate immune checkpoint, correlating with poor clinical outcomes in lung cancer. CEO Purnanand Sarma expressed excitement about the progress, highlighting IL-38's overexpression in tumors with high unmet clinical need. The development aligns with Immunome's goal to innovate antibody therapeutics in oncology.
FAQ
What is the current stock price of Immunome (IMNM)?
What is the market cap of Immunome (IMNM)?
What does Immunome, Inc. specialize in?
What is the core technology platform of Immunome?
What are the primary focus areas for Immunome?
Can you name some of Immunome's key pipeline assets?
Where is Immunome, Inc. based?
What is the goal of Immunome's development strategy?
How does Immunome identify high-affinity antibodies?
What distinguishes Immunome's approach to immunotherapy?
How does Immunome plan to impact cancer treatment?
What recent achievements has Immunome made?
